Bilateral Lipoadenoma of the Adrenal Glands and Humeral Brown Tumor: An Unusual Association.

Case Rep Endocrinol

Department of Endocrinology-Diabetology and Nutrition, Mohammed VI University Hospital Center, Faculty of Medicine and Pharmacy, University of Mohammed 1st, Oujda, Morocco.

Published: August 2021

Adrenal adenolipomas are rare lipomatous adrenal tumors that can be either functional or not. Only 7 cases have been reported in the English literature so far. However, brown tumors are benign, rare, historical lesions, with histological similarity to giant tumors that can be encountered in 1% of all primary hyperparathyroidism cases. We report the case of an unusual association of bilateral lipoadenoma of the adrenal glands and humeral brown tumor in a 35-year-old patient. He presented to the emergency department with a pathological fracture of the left humerus secondary to a brown tumor. The medical investigations have concluded to primary hyperparathyroidism. The screening for multiple endocrine neoplasia type 1 revealed the presence of bilateral nonsecreting adrenal masses whose anatomopathological study concluded adenolipomas. Adrenal tumors may constitute a part of multiple endocrine neoplasia type 1 in 20 to 40% of cases. In this view, it is necessary to check for the presence of other endocrine gland tumor locations such as primary hyperparathyroidism, neuroendocrine tumors of the duodenum and pancreas, or pituitary adenomas.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8416393PMC
http://dx.doi.org/10.1155/2021/4870493DOI Listing

Publication Analysis

Top Keywords

brown tumor
12
primary hyperparathyroidism
12
bilateral lipoadenoma
8
lipoadenoma adrenal
8
adrenal glands
8
glands humeral
8
humeral brown
8
unusual association
8
adrenal tumors
8
multiple endocrine
8

Similar Publications

Irreversible Electroporation and β-Glucan Induced Trained Innate Immunity for the Treatment of Pancreatic Ductal Adenocarcinoma: A Phase II Study.

J Am Coll Surg

January 2025

Division of Immunotherapy, The Hiram C. Polk Jr., MD Department of Surgery, Immuno-Oncology Program, Brown Cancer Center, University of Louisville School of Medicine, Louisville, KY, USA.

Introduction: Irreversible electroporation(IRE) has augmented the effects of certain immunotherapies in pancreatic cancer(PDA). Yeast-derived particulate beta-glucan induces trained innate immunity and has successfully reduces murine PC tumor burden. This is a Phase II study to test the hypothesis that IRE may augment beta-glucan induced trained immunity in patients with PDA.

View Article and Find Full Text PDF

Maturation of conventional dendritic cells (cDCs) is crucial for maintaining tolerogenic safeguards against auto-immunity and for promoting immunogenic responses to pathogens and cancer. The subcellular mechanism for cDC maturation remains poorly defined. We show that cDCs mature by leveraging an internal reservoir of cholesterol (harnessed from extracellular cell debris and generated by de novo synthesis) to assemble lipid nanodomains on cell surfaces of maturing cDCs, enhance expression of maturation markers and stabilize immune receptor signaling.

View Article and Find Full Text PDF

Art of TIL immunotherapy: SITC's perspective on demystifying a complex treatment.

J Immunother Cancer

January 2025

Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA

In a first for solid cancers, cellular immunotherapy has entered standard of care in the treatment of patients with metastatic melanoma. The infusion of autologous tumor-infiltrating T lymphocytes (TIL) is capable of mediating durable tumor regression and is now Food and Drug Administration-approved for patients with disease refractory to immune checkpoint inhibitors. Since the advent of chimeric antigen receptor (CAR) T cells for patients with hematological malignancies, a growing network of centers capable of delivering effector T cell products to patients has developed.

View Article and Find Full Text PDF

CT, MRI, and FDG PET/CT in the Assessment of Lymph Node Involvement in Pediatric Hodgkin Lymphoma: An Expert Consensus Definition by an International Collaboration on Staging Evaluation and Response Criteria Harmonization for Children, Adolescent, and Young Adult Hodgkin Lymphoma (SEARCH for CAYAHL).

Radiology

January 2025

From the Department of Radiology, University Hospital Halle, Ernst-Grube-Strasse 40, 06120 Halle (Saale), Germany (D.S., J.S., J.M.B.); Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany (L.K., T.W.G., R.K.); Diagnostic Imaging and Pediatrics, Warren Alpert Medical School, Brown University, Providence, RI (K.M.M.); Department of Pediatric Radiology, Imaging and Radiation Oncology, Core-Rhode Island, Providence, RI (K.M.M.); Department of Oncology, St Jude Children's Research Hospital, Memphis, Tenn (J.E.F.); Department of Pediatric Hematology and Oncology, University Hospital Giessen-Marburg, Giessen, Germany (C.M.K., D.K.); Medical Faculty of the Martin Luther University of Halle-Wittenberg, Halle (Saale) Germany (C.M.K.); Department of Radiology, University of Wisconsin-Madison, Madison, Wis (S.Y.C.); Roswell Park Comprehensive Cancer Center, Buffalo, NY (K.M.K.); Department of Radiation Oncology, Medical Faculty of the Martin-Luther-University, Halle (Saale), Germany (T.P., D.V.); Department of Radiation Oncology, Mayo Clinic-Jacksonville, Jacksonville, Fla (B.S.H.); Department of Radio-Oncology, Medical University Vienna, Vienna, Austria (K.D.); and Department of Radiology, Boston Children's Hospital and Harvard Medical School, Boston, Mass (S.D.V.).

Staging of pediatric Hodgkin lymphoma is currently based on the Ann Arbor classification, incorporating the Cotswold modifications and the Lugano classification. The Cotswold modifications provide guidelines for the use of CT and MRI. The Lugano classification emphasizes the importance of CT and PET/CT in evaluating both Hodgkin lymphoma and non-Hodgkin lymphoma but focuses on adult patients.

View Article and Find Full Text PDF

Characterization of Tumor Antigens from Multi-omics Data: Computational Approaches and Resources.

Genomics Proteomics Bioinformatics

January 2025

Center for Epigenetics and Disease Prevention, Institute of Biosciences and Technology, Texas A&M University, Houston, TX 77030, USA.

Tumor-specific antigens, also known as neoantigens, have potential utility in anti-cancer immunotherapy, including immune checkpoint blockade (ICB), neoantigen-specific T cell receptor-engineered T (TCR-T), chimeric antigen receptor T (CAR-T), and therapeutic cancer vaccines (TCVs). After recognizing presented neoantigens, the immune system becomes activated and triggers the death of tumor cells. Neoantigens may be derived from multiple origins, including somatic mutations (single nucleotide variants, insertion/deletions, and gene fusions), circular RNAs, alternative splicing, RNA editing, and polymorphic microbiome.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!